Can TG Therapeutics establish BRIUMVI superiority without a head-to-head clinical trial?
A peer-reviewed five-year indirect comparison associates BRIUMVI with lower modeled disability progression risk than ocrelizumab and ofatumumab. The findings support TG Therapeutics' commercial evidence strategy but cannot establish head-to-head superiority.
